Abstract
The information of the complete genome sequences of Trypanosoma cruzi revealed that its genome contains nearly to 10,000 protein-coding genes. This vast amount of new information allows the identification of therapeutic targets in an accurate and undoubtedly forms. The current post-genomic period is a special moment in the anti-T. cruzi drug discovery and development ushering this moment as the anti-Chagas drug discovery era. In this review we describe, from a medicinal chemistry point of view, several identified potential biological targets for drugs development. We discuss the validity and druggability as anti-Chagas objectives of prenyl converting and transferring enzymes, cAMP-specific phosphodiesterases, polyamine and trypanothione synthetic pathways, triosephosphate isomerase, α-hydroxyacid dehydrogenases and trans-sialidase.
Keywords: Chagas' disease, enzymatic inhibitors, drugs development, Trypanosoma cruzi, ergosterol biosynthetic pathway, trypanothione reductase, farnesyltransferase inhibitors, cAMP-specific phosphodiesterases, Dipyridamole, sulfinyl radicals, glutathionylated products
Current Enzyme Inhibition
Title: Targets for Anti-T. cruzi Drugs in the Post-Genomic Era
Volume: 6 Issue: 4
Author(s): Alicia Merlino, Mercedes Gonzalez and Hugo Cerecetto
Affiliation:
Keywords: Chagas' disease, enzymatic inhibitors, drugs development, Trypanosoma cruzi, ergosterol biosynthetic pathway, trypanothione reductase, farnesyltransferase inhibitors, cAMP-specific phosphodiesterases, Dipyridamole, sulfinyl radicals, glutathionylated products
Abstract: The information of the complete genome sequences of Trypanosoma cruzi revealed that its genome contains nearly to 10,000 protein-coding genes. This vast amount of new information allows the identification of therapeutic targets in an accurate and undoubtedly forms. The current post-genomic period is a special moment in the anti-T. cruzi drug discovery and development ushering this moment as the anti-Chagas drug discovery era. In this review we describe, from a medicinal chemistry point of view, several identified potential biological targets for drugs development. We discuss the validity and druggability as anti-Chagas objectives of prenyl converting and transferring enzymes, cAMP-specific phosphodiesterases, polyamine and trypanothione synthetic pathways, triosephosphate isomerase, α-hydroxyacid dehydrogenases and trans-sialidase.
Export Options
About this article
Cite this article as:
Merlino Alicia, Gonzalez Mercedes and Cerecetto Hugo, Targets for Anti-T. cruzi Drugs in the Post-Genomic Era, Current Enzyme Inhibition 2010; 6 (4) . https://dx.doi.org/10.2174/157340810794578533
DOI https://dx.doi.org/10.2174/157340810794578533 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Cardiovascular Manifestations of COVID-19
Current Cardiology Reviews Fatty Liver and Ischemia/Reperfusion: Are there Drugs Able to Mitigate Injury?
Current Medicinal Chemistry Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Prevention of Left Ventricular Remodelling after Acute Myocardial Infarction: An Update
Recent Patents on Cardiovascular Drug Discovery Green Tea Attenuates Cardiovascular Remodeling and Metabolic Symptoms in High Carbohydrate-Fed Rats
Current Pharmaceutical Biotechnology Autophagy: For Better or for Worse, in Good Times or in Bad Times …
Current Molecular Medicine Electrochemical-Based Biosensors: New Diagnosis Platforms for Cardiovascular Disease
Current Medicinal Chemistry Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design Myocardial Contrast Echocardiography: Role in Clinical Cardiology
Current Vascular Pharmacology Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets
Current Drug Targets Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets
Current Pharmaceutical Design Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling
Current Pharmaceutical Design Methods for Identifying Cardiovascular Agents: A Review
Recent Patents on Cardiovascular Drug Discovery Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
Current Pharmaceutical Design Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design